Collectively, our results highlight a new anticancer mechanism of hirudin in which hirudin‐induced inhibition of glioma progression through autophagy activation is likely achieved by inhibition of the mTOR signalling pathway, thus providing a molecular basis for hirudin as a potential and effective clinical drug for glioma therapy. Here, MTOR is linked to glioma.